Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1),Journal of the American Academy of Dermatology

当前位置： X-MOL 学术 › J. Am. Acad. Dermatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Journal of the American Academy of Dermatology ( IF 12.8 ) Pub Date : 2024-07-23 , DOI: 10.1016/j.jaad.2024.06.097
Brett King ₁ , Maryanne M Senna ₂ , Natasha A Mesinkovska ₃ , Charles Lynde ₄ , Matthew Zirwas ₅ , Catherine Maari ₆ , Vimal H Prajapati ₇ , Sheetal Sapra ₈ , Pawel Brzewski ₉ , Lawrence Osman ₁₀ , Sameh Hanna ₁₁ , Marni C Wiseman ₁₂ , Colleen Hamilton ₁₃ , James Cassella ₁₃

Affiliation

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Department of Dermatology, Lahey Hair Loss Center of Excellence, Lahey Hospital and Medical Center, Burlington, Massachusetts.
Department of Dermatology, University of California, Irvine, California.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Lynderm Research Inc., Probity Medical Research, Markham, Ontario, Canada.
DOCS Dermatology, Columbus, Ohio.
Faculty of Medicine, Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
Division of Dermatology, Department of Medicine, and Sections of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Probity Medical Research, Skin Health & Wellness Centre, Calgary, Alberta, Canada.
Institute of Cosmetic and Laser Surgery, Oakville, Ontario, Canada.
Department of Dermatology, Jagiellonian University, Krakow, Poland.
Quest Dermatology Research, Northridge, California.
Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; Dermatology On Bloor, Toronto, Ontario, Canada.
Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Sun Pharmaceutical Industries, Inc., Lexington, Massachusetts.

Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA.

中文翻译：

口服选择性 Janus 激酶抑制剂 deuruxolitinib 在成人斑秃患者中的疗效和安全性：3 期随机对照试验（THRIVE-AA1）的结果

斑秃（AA）是一种脱发疾病，会严重影响生活质量。Janus 激酶（JAK）抑制剂，包括 deuruxolitinib，先前已证明 AA 中有显着的头发再生。

更新日期：2024-07-23

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南